Deregistration notice
Open the filing on sec.gov
Theravance Biopharma, Inc. (TBPH)
TBPH · Pharmaceutical Preparations · George Town, Grand Cayman, CA · filing with the SEC since 2013
Grade6.3
◀ Past 5.6● Present 7.4▶ Future 5.4
The companyfiscal 2025, as filed
Revenue$107M+66.9%
Net income$106M+287.7%
Earnings per share$2.06+279.1%
Operating cash flow$239M+2168.0%
Cash$168M+344.0%
Debtn/a
Shareholders’ equity$297M+69.0%
Shares, diluted51.5M+5.4%
Return on equity35.7%
The recordfrom its filings
Filings in 202682
Newest filingOct 5 · 15-12G
Annual reportMar 23, 2026
Quarterly reportAug 11, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$3.9M
Insider buys, 12 months$0.00
Patents granted265
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Revenue $104MNet income $53.8MCash from operations $53.7Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Activist holder update, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.